163 related articles for article (PubMed ID: 2436634)
1. [Interferons, interleukin-2 and tumor necrosis factor. New approaches to cancer therapy].
Oettgen HF
Arzneimittelforschung; 1987 Feb; 37(2A):251-5. PubMed ID: 2436634
[TBL] [Abstract][Full Text] [Related]
2. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
Wirth M
Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
[TBL] [Abstract][Full Text] [Related]
3. Interleukins, interferons and tumor necrosis factor in cancer treatment.
Krigel RL
AAOHN J; 1987 Apr; 35(4):159-62. PubMed ID: 2950885
[No Abstract] [Full Text] [Related]
4. [Cytokines in tumor therapy].
Lindemann A; Oster W; Herrmann F; Mertelsmann R
Arzneimittelforschung; 1988 Mar; 38(3A):466-9. PubMed ID: 2456072
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapy of melanoma with cytokines and lymphocytes.
Bear HD; Hamad GG; Kostuchenko PJ
Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
[TBL] [Abstract][Full Text] [Related]
6. [Alpha interferons--new therapeutic modalities].
Bajcetić M; Zigon N; Samardzić R; Beleslin DB
Med Pregl; 1998; 51(3-4):135-9. PubMed ID: 9611956
[TBL] [Abstract][Full Text] [Related]
7. [Possibilities and limits of the use of interferons in the clinic].
Ludwig CU
Schweiz Med Wochenschr; 1989 Nov; 119(44):1539-43. PubMed ID: 2479977
[TBL] [Abstract][Full Text] [Related]
8. [Interferons in the therapy of solid tumors].
Tomao S; Mozzicafreddo A; Raffaele M; Romiti A; Papò MA; Campisi C
Clin Ter; 1995; 146(8-9):491-502. PubMed ID: 8536432
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of metastatic renal cell cancer].
Manseck A; Wirth M
Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
[TBL] [Abstract][Full Text] [Related]
10. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
11. Lymphokines and cytokines.
Wagstaff J; Melief KJ
Cancer Chemother Biol Response Modif; 1987; 9():432-53. PubMed ID: 2484327
[TBL] [Abstract][Full Text] [Related]
12. [Recent trends in cancer treatment using cytokines].
Urushizaki I
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):897-905. PubMed ID: 2471455
[TBL] [Abstract][Full Text] [Related]
13. Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC).
Oldham RK; Lewko WM; Good RW; Sharp E
In Vivo; 1994; 8(5):653-63. PubMed ID: 7537108
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
15. Current status of interferons in the treatment of cancer.
Hansen RM; Borden EC
Oncology (Williston Park); 1992 Nov; 6(11):19-24; discussion 26, 29. PubMed ID: 1280153
[TBL] [Abstract][Full Text] [Related]
16. [Cytokines and monoclonal antibodies. Immunologic approaches to tumor therapy].
Pfreundschuh M
Fortschr Med; 1986 Dec; 104(47-48):973-6. PubMed ID: 2434398
[No Abstract] [Full Text] [Related]
17. Cancer therapy by biological response modifiers.
Herberman RB
Clin Physiol Biochem; 1987; 5(3-4):238-48. PubMed ID: 2441918
[TBL] [Abstract][Full Text] [Related]
18. [Progress in the therapy of malignant tumors].
Gropp C
Internist (Berl); 1987 Jan; 28(1):44-52. PubMed ID: 2437067
[No Abstract] [Full Text] [Related]
19. The role of interleukin-2 in the biotherapy of cancer.
Parkinson DR
Oncol Nurs Forum; 1989; 16(6 Suppl):16-20. PubMed ID: 2687810
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
